Cell focus offers new hope
An Australian biotechnology company says it has come up with an innovative drug that has the potential to transform the treatment of people with cancer – and make a significant dent in a $100 billion global market.
The company is Noxopharm, based in Sydney. Its CEO, Dr Graham Kelly, sees huge potential for its anti-cancer drug, NOX66.
‘‘We believe NOX66 is going to change the face of cancer therapy,’’ he says. ‘‘It’s the only anti-cancer drug we know of that makes cancer cells more sensitive to radiotherapy and chemotherapy so that those therapies become dramatically more effective, but without making them any more unsafe.’’
To view Review please download PDF attached:
Download this document
